K Kelly

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi The benefits of achieving stable disease in advanced lung cancer
    Karen Kelly
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:957-63; discussion 963, 968-70. 2003
  2. ncbi Irinotecan in small-cell lung cancer: current data
    K Kelly
    University of Colorado Cancer Center, Denver, CO, USA
    Clin Lung Cancer 2:S4-8. 2001
  3. ncbi Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?
    K Kelly
    Lung Cancer Program, University of Colorado Cancer Center, Denver 80262, USA
    Lung Cancer 20:85-91. 1998
  4. ncbi An elderly man with resectable lung cancer
    Karen Kelly
    Clinical Thoracic Oncology Program, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 18:234-40. 2004
  5. ncbi Current role of irinotecan in the treatment of non-small-cell lung cancer
    Karen Kelly
    Division of Medical Oncology, University of Colorado Health Sciences Center, Denver 80262, USA
    Oncology (Williston Park) 16:1153-62, 1165; discussion 1165-6 passim. 2002
  6. ncbi The role of targeted agents in adjuvant therapy for non-small cell lung cancer
    Karen Kelly
    University of Colorado Health Sciences Center, PO Box 6511, Aurora, CO 80010, USA
    Clin Cancer Res 11:5027s-5029s. 2005
  7. ncbi Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status
    Karen Kelly
    University of Colorado Cancer Center, 12801 East 17th Avenue, Room L18 8122, Aurora, CO 80010, USA
    Semin Oncol 31:3-7. 2004
  8. ncbi The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer
    K Kelly
    Lung Cancer Program, University of Colorado Cancer Center, Denver, USA
    Ann Oncol 10:S53-6. 1999
  9. ncbi Medical treatment of lung cancer
    K Kelly
    Lung Cancer Program and the Division of Medical Oncology, The University of Colorado Cancer Center, Denver, USA
    J Thorac Imaging 14:257-65. 1999
  10. ncbi A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    K Kelly
    Division of Medical Oncology, Lung Cancer Program, University of Colorado Cancer Center, Denver 80262, USA
    Clin Cancer Res 6:3474-9. 2000

Detail Information

Publications60

  1. ncbi The benefits of achieving stable disease in advanced lung cancer
    Karen Kelly
    Division of Medical Oncology, University of Colorado, Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 17:957-63; discussion 963, 968-70. 2003
    ..Thus, with the introduction of new molecular-targeted agents, stable disease with clinical benefit should become an important goal of anticancer therapy...
  2. ncbi Irinotecan in small-cell lung cancer: current data
    K Kelly
    University of Colorado Cancer Center, Denver, CO, USA
    Clin Lung Cancer 2:S4-8. 2001
    ..Preliminary results are encouraging. This article will highlight the exciting results achieved with irinotecan in SCLC and discuss its promising future in this disease...
  3. ncbi Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?
    K Kelly
    Lung Cancer Program, University of Colorado Cancer Center, Denver 80262, USA
    Lung Cancer 20:85-91. 1998
    ..With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category...
  4. ncbi An elderly man with resectable lung cancer
    Karen Kelly
    Clinical Thoracic Oncology Program, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Oncology (Williston Park) 18:234-40. 2004
  5. ncbi Current role of irinotecan in the treatment of non-small-cell lung cancer
    Karen Kelly
    Division of Medical Oncology, University of Colorado Health Sciences Center, Denver 80262, USA
    Oncology (Williston Park) 16:1153-62, 1165; discussion 1165-6 passim. 2002
    ..Early trials of irinotecan in combination with cisplatin or carboplatin along with radiation therapy have reported overall response rates of 60% to 67%. The approach appears to have potential and warrants further study...
  6. ncbi The role of targeted agents in adjuvant therapy for non-small cell lung cancer
    Karen Kelly
    University of Colorado Health Sciences Center, PO Box 6511, Aurora, CO 80010, USA
    Clin Cancer Res 11:5027s-5029s. 2005
    ..Criteria for selecting promising targeted therapies and optimal trial designs to evaluate them expeditiously in the adjuvant setting are clearly needed...
  7. ncbi Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status
    Karen Kelly
    University of Colorado Cancer Center, 12801 East 17th Avenue, Room L18 8122, Aurora, CO 80010, USA
    Semin Oncol 31:3-7. 2004
    ..A greater understanding of PS scores and the factors that affect them can be gained through PS2-specific clinical trials, which can lead to the development of better PS instruments to aid in making therapeutic decisions...
  8. ncbi The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer
    K Kelly
    Lung Cancer Program, University of Colorado Cancer Center, Denver, USA
    Ann Oncol 10:S53-6. 1999
    ..As monotherapy, gemcitabine may make a valuable contribution to those patients with a poor performance status or comorbid diseases desiring treatment studies in this setting should also be considered...
  9. ncbi Medical treatment of lung cancer
    K Kelly
    Lung Cancer Program and the Division of Medical Oncology, The University of Colorado Cancer Center, Denver, USA
    J Thorac Imaging 14:257-65. 1999
    ..This article reviews the current treatment strategies for non-small cell lung cancer and small cell lung cancer as well as discusses future treatments, including the exciting biologic agents that are in clinical trials...
  10. ncbi A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer
    K Kelly
    Division of Medical Oncology, Lung Cancer Program, University of Colorado Cancer Center, Denver 80262, USA
    Clin Cancer Res 6:3474-9. 2000
    ..The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC...
  11. ncbi New chemotherapy agents for small cell lung cancer
    K Kelly
    University of Colorado Health Sciences Center, Denver, CO, USA
    Chest 117:156S-162S. 2000
    ..Clearly, new chemotherapy agents with novel mechanisms of action are needed...
  12. ncbi Treatment of extensive stage small cell lung cancer
    K Kelly
    University of Colorado Cancer Center, Denver, CO 80220, USA
    Cancer Treat Res 105:253-76. 2001
    ..We enter the next century enthusiastic about the array of new chemotherapeutic agents to evaluate and fascinated by the biological agents with the hope of achieving dramatic improvements in survival for our patients with SCLC...
  13. ncbi Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial
    K Kelly
    University of Colorado, Denver, CO, USA
    J Clin Oncol 19:3210-8. 2001
    ..CONCLUSION: PC is equally efficacious as VC for the treatment of advanced non--small-cell lung cancer. PC is less toxic and better tolerated but more expensive than VC. New treatment strategies should be pursued...
  14. ncbi Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group
    K Kelly
    University of Colorado, Denver, CO 80262, USA
    Clin Cancer Res 7:2325-9. 2001
    ..These results provide the largest database for the ongoing randomized Intergroup trial comparing PET to cisplatin+etoposide in PS-0-1 patients with ES-SCLC...
  15. ncbi New combinations in the treatment of lung cancer: a time for optimism
    P A Bunn
    University of Colorado Cancer Center, Denver, CO 80262, USA
    Chest 117:138S-143S. 2000
    ..Future research will focus on using these agents in two- and three-drug regimens as radiation sensitizers and in combination programs with new drugs and biological agents with apparent activity against this disease...
  16. ncbi The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
    G J Weiss
    Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO, USA
    Ann Oncol 18:453-60. 2007
    ....
  17. ncbi Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer: a time for reassessment?
    P A Bunn
    Lung Cancer Program and Departments of Medicine, University of Colorado Cancer Center, Denver, CO 80262, USA
    Chest 117:119S-122S. 2000
    ..Newer active agents, such as paclitaxel, vinorelbine, and gemcitabine, may be able to advance the cure rate even further. Radiotherapy, which has been shown to decrease the rate of local recurrence, may play a role as well...
  18. ncbi Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer
    Christiane D Thienelt
    Division of Medical Oncology and Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    J Clin Oncol 23:8786-93. 2005
    ..Secondary objectives included efficacy and paclitaxel and carboplatin pharmacokinetics during cetuximab treatment...
  19. ncbi Gefitinib: phase II and III results in advanced non-small cell lung cancer
    Karen Kelly
    University of Colorado Cancer Center, Denver 80262, USA
    Semin Oncol 31:93-9. 2004
    ..Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer...
  20. ncbi Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy
    Paul A Bunn
    Department of Medicine, University of Colorado Cancer Center and University of Colorado Health Sciences Center, Aurora, 80045, USA
    Clin Cancer Res 12:3652-6. 2006
  21. ncbi A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer
    Patrapim Sunpaweravong
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80010, USA
    Invest New Drugs 24:213-21. 2006
    ..This novel approach produced similar efficacy results to current two drug regimens but was associated with significant neutropenia. Alternative strategies to increase complete response rates and survival are needed...
  22. pmc Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
    Fred R Hirsch
    Southwest Oncology Group, San Antonio, USA
    J Clin Oncol 26:3351-7. 2008
    ..Here, we evaluate EGFR FISH as a predictive marker in NSCLC patients receiving the EGFR monoclonal antibody inhibitor cetuximab plus chemotherapy...
  23. ncbi Treatment of non-small-cell lung cancer in older persons
    Michele Basche
    University of Colorado Health Sciences Center, Division of Medical Oncology, Denver, Colorado, USA
    Oncology (Williston Park) 17:31-9; discussion 43-4, 47-8. 2003
    ..Participation of older patients in clinical trials designed to assess efficacy, toxicity, and quality-of-life outcomes for recently developed treatment modalities in this population is critical...
  24. ncbi Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results
    Kavita Garg
    Department of Radiology, University of Colorado, Denver Veterans Affairs Medical Center, USA
    Radiology 225:506-10. 2002
    ..To assess the feasibility of conducting a randomized controlled trial for lung cancer screening...
  25. ncbi Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Semin Oncol 29:87-94. 2002
    ..These observations lead to the studies of the combination of exisulind and docetaxel in preclinical and clinical studies in human lung cancer described in this article...
  26. ncbi Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
    Glen J Weiss
    University of Colorado Health Sciences Center, Division of Medical Oncology Center, Aurora, CO 80010, USA
    J Clin Oncol 24:4405-11. 2006
    ..However, few published data exist on the efficacy and tolerability of second-line cytotoxic therapy in this population...
  27. ncbi The promise of stereotactic body radiation therapy in a new era of oncology
    Brian D Kavanagh
    University of Colorado Comprehensive Cancer Center, Aurora, CO, USA
    Front Radiat Ther Oncol 40:340-51. 2007
    ..Here, the history of SBRT is briefly reviewed, and a projection of the anticipated role of SBRT within the context of multimodality cancer treatment regimens of the future is presented...
  28. ncbi Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer
    Glen J Weiss
    Division of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO 80010, USA
    Clin Lung Cancer 8:335-8. 2007
    ..The addition of bevacizumab to carboplatin/paclitaxel in the first-line setting was shown to improve survival and response. We assessed pemetrexed and bevacizumab compared with pemetrexed alone in the salvage setting...
  29. ncbi EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome
    Lynne T Bemis
    Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, CO, USA
    Lancet Oncol 8:559-60. 2007
  30. ncbi A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors
    Samir E Witta
    University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Clin Cancer Res 10:7229-37. 2004
    ..In an orthotopic model of human non-small-cell lung cancer, the combination of exisulind and docetaxel prolonged survival in athymic nude rats, forming the basis of this phase I combination study...
  31. pmc A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer
    Karen Kelly
    Pulmonary 111A, Denver VA Medical Center, 1055 Clermont Street, Denver, CO 80220, USA
    Cancer Prev Res (Phila) 2:440-9. 2009
    ..Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of alpha tocopherol did not affect toxicity...
  32. ncbi Combinations of three chemotherapeutic agents and two chemotherapeutic agents plus a targeted biologic agent in the treatment of advanced non small-cell lung cancer
    P A Bunn
    University of Colorado Cancer Center, 4200 East Ninth Avenue, B188, Denver, CO 80262, USA
    Clin Lung Cancer 2:S23-8. 2000
    ..Several combinations of doublet chemotherapy with a new targeted agent have completed phase II trials with encouraging results. Some of these new triplets are now in phase III randomized trials...
  33. ncbi SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC)
    W A Franklin
    University of Colorado HSC, Aurora, CO University of California Davis Cancer Center, Sacramento, CA M D Anderson Cancer Center, Houston, TX Fred Hutchinson Cancer Research Center, Seattle, WA Southwest Oncology Group Statistical Center, Seattle, WA University of Colorado Denver, Denver, CO University of Kansas, Kansas City, KS
    J Clin Oncol 27:11076. 2009
    ....
  34. doi Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium
    Ross Camidge
    Department of Medicine, University of Colorado, Colorado, USA
    J Thorac Oncol 4:930-5. 2009
    ....
  35. ncbi Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial
    Glen J Weiss
    TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale, AZ, USA
    J Thorac Oncol 2:933-8. 2007
    ..This multicenter, phase II clinical trial was conducted to evaluate the activity of the combination of docetaxel and exisulind in advanced non-small cell lung cancer (NSCLC) patients who failed a prior platinum-containing regimen...
  36. ncbi Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, MA 02135, USA
    J Thorac Oncol 1:991-5. 2006
    ....
  37. doi Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor
    Karen Kelly
    Kansas Masonic Cancer Research Institute, University of Kansas Cancer Center, Kansas City, KS 66160, USA
    J Thorac Oncol 3:664-73. 2008
    ..Finally, emerging data combining EGFR and VEGF inhibitors suggest that multiple pathway inhibition may be more effective than targeting a single pathway...
  38. doi Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
    Karen Kelly
    University of Kansas Medical Center, Kansas City, KS 66160, USA
    J Clin Oncol 26:2450-6. 2008
    ..Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease...
  39. doi Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
    F Anthony Greco
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, United States
    Lung Cancer 61:82-90. 2008
    ..The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines. This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC...
  40. ncbi Current treatment paradigms for locally advanced non-small cell lung cancer
    James R Rigas
    Dartmouth Medical School, Lebanon, NH 03756, USA
    J Thorac Oncol 2:S77-85. 2007
    ..This article will review the current treatment strategies for stage III NSCLC...
  41. doi Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials
    Primo N Lara
    University of California Davis Cancer Center, 4501 X St, Sacramento, CA 95817, USA
    J Clin Oncol 26:463-7. 2008
    ....
  42. ncbi Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
    Michael P Fanucchi
    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
    J Clin Oncol 24:5025-33. 2006
    ..To evaluate the efficacy and toxicity of bortezomib +/- docetaxel as second-line therapy in patients with relapsed or refractory advanced non-small-cell lung cancer (NSCLC)...
  43. ncbi Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504)
    David R Gandara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:116-21. 2006
    ..Survival outcomes were compared with a predecessor study (S9019) with identical eligibility, staging criteria, and treatment, excepting docetaxel consolidation...
  44. ncbi Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer
    Scott D Ramsey
    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 94:291-7. 2002
    ..There were no statistically significant differences in survival or cancer-related quality of life between the treatment arms...
  45. ncbi Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Mark G Kris
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 290:2149-58. 2003
    ....
  46. ncbi Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel
    Martin J Edelman
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 10:5022-6. 2004
    ....
  47. ncbi Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer
    Christian Monnerat
    Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 10:5439-46. 2004
    ..It is also known for significant toxicity, which makes it unsuitable for certain patients. Our purpose was to evaluate the efficacy and toxicity of a promising cisplatin-free combination, gemcitabine plus pemetrexed, in NSCLC...
  48. ncbi HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum
    Roman Perez-Soler
    Department of Oncology, Hofheimer 100, Montefiore Medical Center Albert Einstein College of Medicine, 111 East 210th Street, Bronx, New York 10467, USA
    Oncologist 10:345-56. 2005
    ..The increasing use of HER1/EGFR-targeted agents makes managing rash important. We hope the outcomes from this Forum provide background for future studies...
  49. ncbi Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel
    Cesare Gridelli
    Division of Medical Oncology, S G Moscati Hospital, Via Circumvallazione 68, 83100 Avellino, Italy
    J Clin Oncol 23:3125-37. 2005
    ..Best supportive care remains important, in addition to chemotherapy or as the exclusive option for patients who are unsuitable for more aggressive treatment...
  50. ncbi Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732
    Harvey B Niell
    University of Tennessee, Memphis, TN 31187, USA
    J Clin Oncol 23:3752-9. 2005
    ....
  51. ncbi Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
    Ramaswamy Govindan
    Washington University School of Medicine, Department of Medical Oncology, 660 S Euclid Ave Box 8056, St Louis, MO 63110, USA
    Lung Cancer 53:331-7. 2006
    ..3%). Complete and partial response rates were 0.7 and 5.6%, respectively, and 40.6% had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7%. The majority of patients did not receive subsequent CT...
  52. ncbi A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials
    Sumithra J Mandrekar
    Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 107:781-92. 2006
    ....
  53. ncbi Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy
    David R Gandara
    Department of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817 2229, USA
    Clin Lung Cancer 7:S93-7. 2005
    ..Herein, we review the rationale for a treatment paradigm employing consolidation docetaxel therapy after concurrent chemotherapy/RT and the results of recent clinical trials using this approach...
  54. ncbi Zones of prevention: the geography of fall injuries in the elderly
    Nikolaos Yiannakoulias
    Health Surveillance Branch, Alberta Health and Wellness, 24th Floor, PO Box 1360, Edmonton, Alta, Canada T5J 2N3
    Soc Sci Med 57:2065-73. 2003
    ..We argue that descriptive geography can enhance the effectiveness of injury prevention programs by identifying zones of high risk, even when the individual-level and contextual factors that explain the underlying patterns are unknown...
  55. doi Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
    George R Simon
    Thoracic Oncology Program and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, MRC 4W, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    J Clin Oncol 26:3567-72. 2008
    ..This clinical study assessed safety and efficacy of pemetrexed plus gemcitabine in chemotherapy-naïve patients with MPeM...
  56. ncbi Tracking the time to recovery after induced loudness reduction
    Yoav Arieh
    J Acoust Soc Am 117:3381-4. 2005
  57. ncbi Novel approaches for the treatment of small cell lung cancer
    Heather Wakelee
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Hematol Oncol Clin North Am 18:499-518. 2004
  58. ncbi Treatment of thymoma: a comparative study between Thailand and the United States and a review of the literature
    Patrapim Sunpaweravong
    Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
    Am J Clin Oncol 27:236-46. 2004
    ..Surgery and radiation remain the backbone of treatment, but the role for chemotherapy is increasing...
  59. ncbi Four-star service
    Karen Kelly
    Nurs Times 101:20-1. 2005
  60. ncbi Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center of Boston, Boston, Massachusetts 02135, USA
    J Thorac Oncol 2:440-4. 2007
    ..This phase II study (S9718) evaluated the antineoplastic activity and tolerability of the combination of gemcitabine and cisplatin in previously untreated patients with extensive stage small cell lung cancer (ES-SCLC)...